Tag Archive for: cancer immunotherapy

Phase 1 Trial of SYNC-T Immunotherapy Reports Longer-Term Survival Data in Prostate Cancer

/in , , /by

Updated results provide longer-term survival data for SYNC-T Therapy SV-102, an experimental personalized immunotherapy evaluated in patients with metastatic prostate cancer. SYNC-T uses a two-step approach. First, a selected tumor lesion undergoes partial cryolysis, releasing patient-specific tumor antigens. An immunotherapy mixture called SV-102 is then injected directly into the treated area. It contains four components: […]

Read more

New Randomized Phase 2 Trial Tests Vaccine Plus PSMA×CD3 Immunotherapy in Biochemical Recurrence

/in , , /by

A new randomized phase 2 trial will test an immunotherapy strategy specifically in men with biochemical recurrence of prostate cancer after local treatment with curative intent, meaning patients whose PSA is rising again after surgery and/or radiotherapy but who are not yet receiving further systemic treatment. The study plans to enrol up to 84 patients […]

Read more

UPDATE: VIR-5500 Receives FDA Fast Track Designation Following Promising Phase 1 Results in mCRPC / mAPMR

/in , , /by

The US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500 (formerly AMX-500), an experimental immunotherapy for patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). The designation is intended to accelerate clinical development and regulatory review, but does not constitute drug approval. VIR-5500 is a bispecific T-cell engager designed to direct […]

Read more

A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes

/in , /by

CAR-T therapy has transformed some blood cancers, but solid tumors remain much more difficult. One major problem is tumor heterogeneity: not every cancer cell expresses the same target, and tumours can change over time. A new preclinical study published in Cancer Immunology Research describes a way to make CAR-T cells more adaptable. The researchers created […]

Read more

Phase 1 Trial: IL‑18–Armored STEAP1 CAR T Cells for Metastatic Castration‑Resistant Prostate Cancer

/in , , /by

IL‑18–armored STEAP1 CAR T cells represent a biologically rational, early‑clinical strategy that combines a well‑validated prostate‑cancer target with next‑generation cytokine armoring designed to overcome the hostile tumour microenvironment and antigen heterogeneity that have limited earlier immunotherapy efforts. STEAP1 (six‑transmembrane epithelial antigen of the prostate 1) was first identified in advanced prostate cancer and is now […]

Read more

Phase 1/2 Trial for CRG-150, a New Approach to Immunotherapy

/in , , , /by

CRG-150 is entering first-in-human testing as an unconventional immunotherapy for patients with relapsed or refra9ctory metastatic prostate cancer and other solid tumors. The autologous, CRISPR-edited cell therapy targets steroid receptor coactivator 3, or SRC-3, in regulatory T cells. Tregs help maintain immune tolerance but can suppress antitumor immunity in prostate cancer. By disrupting SRC-3, CRG-150 […]

Read more

Phase 1 Trial: Boosting Sipuleucel‑T with N‑803

/in , , /by

Fifteen years after sipuleucel‑T became the first cellular immunotherapy to show an overall‑survival benefit in metastatic castration‑resistant prostate cancer (mCRPC), a new phase Ib trial at Washington University is testing whether adding the IL‑15 superagonist N‑803 (Anktiva) can turn that modest, durable survival signal into a stronger, more consistent immune attack on metastatic disease. The […]

Read more

Radioligand Therapy Plus CAR‑T: A New Strategy to Reprogram the Prostate Cancer Microenvironment

/in , /by

A new preclinical study shows that radioligand therapy (RLT) can directly enhance CAR‑T cell efficacy in metastatic castration-resistant prostate cancer (mCRPC), addressing two major barriers: antigen heterogeneity and an immunosuppressive tumor microenvironment (TME). Researchers combined 177Lu‑PSMA‑617 (Pluvicto) with PSCA-targeted CAR‑T cells in sequence (RLT → cyclophosphamide → CAR‑T). Compared to either treatment alone, the combination […]

Read more

PARP Inhibition Combined with Targeted T-Cell Activation Drives Polyclonal Antitumor Immunity in mCRPC

/in , /by

A novel therapeutic strategy combining PARP inhibition with selective T-cell receptor β chain activation is showing promising potential to overcome immune resistance in metastatic castration-resistant prostate cancer (mCRPC). This approach pairs olaparib, a well-established PARP inhibitor, with a bifunctional T-cell agonist (STAR0602) designed to selectively expand specific T-cell subsets through targeted delivery of interleukin-2. Prostate […]

Read more

BAT Before Sipuleucel-T in mCRPC: Immune Priming?

/in , , /by

Bipolar androgen therapy (BAT) given before sipuleucel‑T appears to increase the rate and magnitude of PA2024‑specific immune responses in men with metastatic castration‑resistant prostate cancer (mCRPC), compared with historical sipuleucel‑T data. The central interpretation is not that BAT by itself generates this immune response, but that BAT may prime the tumor and immune environment so […]

Read more